PSMA-Targeted Nanotheranostics for Imaging and Radiotherapy of Prostate Cancer

PSMA-Targeted Nanotheranostics for Imaging and Radiotherapy of Prostate Cancer

Targeted nanotheranostic systems offer significant benefits due to the integration of diagnostic and therapeutic functionality, promoting personalized medicine. In recent years, prostate-specific membrane antigen (PSMA) has emerged as an ideal theranostic target, fueling multiple new drug approvals...

Full description

Bibliographic Details
Main Authors:	Niranjan Meher, Henry F. VanBrocklin, David M. Wilson, Robert R. Flavell
Format:	Article
Language:	English
Published:	MDPI AG 2023-02-01
Series:	Pharmaceuticals
Subjects:	prostate-specific membrane antigen (PSMA) nanocarriers nanoparticle enhanced permeability and retention (EPR) effect small-molecule PSMA inhibitors prostate cancer theranostics
Online Access:	https://www.mdpi.com/1424-8247/16/2/315

Similar Items

Prostate-Specific Membrane Antigen (PSMA) Theranostics for Treatment of Oligometastatic Prostate Cancer
by: Kristin A. Plichta, et al.
Published: (2021-11-01)

A New Class of PSMA-617-Based Hybrid Molecules for Preoperative Imaging and Intraoperative Fluorescence Navigation of Prostate Cancer
by: Ann-Christin Eder, et al.
Published: (2022-02-01)

PSMA-Targeting Radiopharmaceuticals for Prostate Cancer Therapy: Recent Developments and Future Perspectives
by: Mohamed El Fakiri, et al.
Published: (2021-08-01)

PSMA theragnostics for metastatic castration resistant prostate cancer
by: Hong Song, et al.
Published: (2022-08-01)

Therapeutic Outcomes of 177Lu-PSMA Targeted Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer: A Single-Center Study
by: Seyed Ali Mirshahvalad, et al.
Published: (2023-01-01)

Incorporating PSMA-Targeting Theranostics Into Personalized Prostate Cancer Treatment: a Multidisciplinary Perspective
by: Thomas S. C. Ng, et al.
Published: (2021-07-01)

Case Report: 18F-PSMA PET/CT Scan in Castration Resistant Prostate Cancer With Aggressive Neuroendocrine Differentiation
by: Marco Bergamini, et al.
Published: (2022-07-01)

Update of PSMA Theranostics in Prostate Cancer: Current Applications and Future Trends
by: Chalermrat Kaewput, et al.
Published: (2022-05-01)

Threshold for defining PSMA-positivity prior to 177Lu-PSMA therapy: a comparison of [68Ga]Ga-PSMA-11 and [18F]F-DCFPyL in metastatic prostate cancer
by: Jan Heilinger, et al.
Published: (2023-09-01)

Current status of PSMA-targeted imaging and therapy
by: Hui Wang, et al.
Published: (2024-01-01)

Pharmacological Optimization of PSMA-Based Radioligand Therapy
by: Suzanne van der Gaag, et al.
Published: (2022-11-01)

Combined biology-guided radiotherapy and Lutetium PSMA theranostics treatment in metastatic castrate-resistant prostate cancer
by: Mathieu Gaudreault, et al.
Published: (2023-03-01)

Radiolabeled PSMA Inhibitors
by: Oliver C. Neels, et al.
Published: (2021-12-01)

PSMA Targeted Molecular Imaging and Radioligand Therapy for Prostate Cancer: Optimal Patient and Treatment Issues
by: Seiji Hoshi, et al.
Published: (2023-08-01)

The Role of PSMA PET/CT in the Primary Diagnosis and Follow-Up of Prostate Cancer—A Practical Clinical Review
by: Anna Rebecca Lisney, et al.
Published: (2022-07-01)

PSMA PET-CT in the Diagnosis and Staging of Prostate Cancer
by: Alexander D. Combes, et al.
Published: (2022-10-01)

Application of 68Ga-PSMA-11 and 18F-PSMA-1007 in prostate cancer
by: Hu Siqi, Zhang Yong
Published: (2022-01-01)

Advanced PSMA-PET/CT Imaging Parameters in Newly Diagnosed Prostate Cancer Patients for Predicting Metastatic Disease
by: Yaniv Yechiel, et al.
Published: (2023-02-01)

Histology and PSMA Expression on Immunohistochemistry in High-Risk Prostate Cancer Patients: Comparison with <sup>68</sup>Ga-PSMA PET/CT Features in Primary Staging
by: Luigia Vetrone, et al.
Published: (2023-03-01)

Synthesis and Preclinical Evaluation of Radio-Iodinated GRPR/PSMA Bispecific Heterodimers for the Theranostics Application in Prostate Cancer
by: Ayman Abouzayed, et al.
Published: (2019-07-01)

Deep learning and radiomics framework for PSMA-RADS classification of prostate cancer on PSMA PET
by: Kevin H. Leung, et al.
Published: (2022-12-01)

Preclinical comparison of [177Lu]Lu-rhPSMA-10.1 and [177Lu]Lu-rhPSMA-10.2 for endoradiotherapy of prostate cancer: biodistribution and dosimetry studies
by: Alexander Wurzer, et al.
Published: (2024-02-01)

Direct comparison of 99mTc-PSMA SPECT/CT and 68Ga-PSMA PET/CT in patients with prostate cancer.
by: Batool Albalooshi, et al.
Published: (2020-01-01)

A convenient total synthesis of PSMA-617: A prostate specific membrane antigen (PSMA) ligand for prostate cancer endotherapeutic applications
by: K.S. Ajish Kumar, et al.
Published: (2022-12-01)

Synthesis and Evaluation of ePSMA-DM1: A New Theranostic Small-Molecule Drug Conjugate (T-SMDC) for Prostate Cancer
by: Erika Murce, et al.
Published: (2023-07-01)

Diagnosing small bowel carcinoid tumor in a patient with oligometastatic prostate cancer imaged with PSMA-Targeted [18F]DCFPyL PET/CT: Value of the PSMA-RADS-3D Designation
by: Eugene Shenderov, et al.
Published: (2018-03-01)

LU-177-PSMA TREATMENT FOR METASTATIC PROSTATE CANCER – CASE EXAMPLES OF MIRACLE RESPONSES
by: K. Kairemo, et al.
Published: (2018-03-01)

Application of PSMA PET/CT Specific Molecular Imaging in Diagnosis of Non-prostate Cancer
by: LIU Teli, et al.
Published: (2019-11-01)

Research Progress of PSMA-Targeted Small Molecule Drugs
by: MU Boshuai;XU Yang;LIU Zhibo
Published: (2021-12-01)

Comparison of the radiolabeled PSMA-inhibitor 111In-PSMA-617 and the radiolabeled GRP-R antagonist 111In-RM2 in primary prostate cancer samples
by: Romain Schollhammer, et al.
Published: (2019-06-01)

New Prostate Cancer Targets for Diagnosis, Imaging, and Therapy: Focus on Prostate-Specific Membrane Antigen
by: Alessia Cimadamore, et al.
Published: (2018-12-01)

Gallium-68 prostate-specific membrane antigen ([68Ga]Ga-PSMA-11) PET for imaging of thyroid cancer: a feasibility study
by: Courtney Lawhn-Heath, et al.
Published: (2020-10-01)

Comparison of PSMA-TO-1 and PSMA-617 labeled with gallium-68, lutetium-177 and actinium-225
by: Catherine Meyer, et al.
Published: (2022-10-01)

Systemic therapy response evaluation in prostate carcinoma with [68Ga]Ga-PSMA-11 PET/CT
by: Kadir Alper Kucuker, et al.
Published: (2022-08-01)

Detection Rate of <sup>18</sup>F-Labeled PSMA PET/CT in Biochemical Recurrent Prostate Cancer: A Systematic Review and a Meta-Analysis
by: Giorgio Treglia, et al.
Published: (2019-05-01)

Optimized <sup>68</sup>Ga-Labeled Urea-Based PSMA-Targeted PET Tracers for Prostate Cancer
by: Yitian Wu, et al.
Published: (2022-08-01)

Current Status of PSMA-Radiotracers for Prostate Cancer: Data Analysis of Prospective Trials Listed on ClinicalTrials.gov
by: Claus Zippel, et al.
Published: (2020-01-01)

Comparison of 68Ga-PSMA PET/CT and multiparametric MRI for the detection of low- and intermediate-risk prostate cancer
by: Chuanchi Zhou, et al.
Published: (2022-02-01)

GRPR versus PSMA: expression profiles during prostate cancer progression demonstrate the added value of GRPR-targeting theranostic approaches
by: Marjolein Verhoeven, et al.
Published: (2023-08-01)

Theranostic 64Cu-DOTHA2-PSMA allows low toxicity radioligand therapy in mice prostate cancer model
by: Marie-Christine Milot, et al.
Published: (2023-01-01)